P
Paola Zaratin
Researcher at Multiple Sclerosis Foundation
Publications - 86
Citations - 2488
Paola Zaratin is an academic researcher from Multiple Sclerosis Foundation. The author has contributed to research in topics: Receptor & Multiple sclerosis. The author has an hindex of 26, co-authored 81 publications receiving 2023 citations. Previous affiliations of Paola Zaratin include Merck Serono & University of Milan.
Papers
More filters
Journal ArticleDOI
Disease-Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple Sclerosis.
Maria Pia Sormani,Nicola De Rossi,Irene Schiavetti,Luca Carmisciano,Cinzia Cordioli,Lucia Moiola,Marta Radaelli,Paolo Immovilli,Marco Capobianco,Maria Trojano,Paola Zaratin,Gioacchino Tedeschi,Giancarlo Comi,Mario Alberto Battaglia,Mario Alberto Battaglia,Francesco Patti,Marco Salvetti +16 more
TL;DR: In this paper, the impact of immunosuppressive and immunomodulatory therapies on the severity of coronavirus disease 2019 (COVID-19) in people with multiple sclerosis (PwMS) was evaluated by multivariate and propensity score (PS)-weighted ordinal logistic models.
Journal ArticleDOI
Interference with Heparin Binding and Oligomerization Creates a Novel Anti-Inflammatory Strategy Targeting the Chemokine System
Zoë Johnson,Marie Kosco-Vilbois,Suzanne Herren,Rocco Cirillo,Valeria Muzio,Paola Zaratin,Michela Carbonatto,Matthias Mack,Amir Smailbegovic,Mark J. Rose,Rebecca Lever,Clive P. Page,Timothy N. C. Wells,Amanda E. I. Proudfoot +13 more
TL;DR: A novel strategy to modulate the inflammatory process in vivo through mutation of the essential heparin-binding site of a proinflammatory chemokine, which abrogates the ability of the protein to form higher-order oligomers, but retains receptor activation.
Journal ArticleDOI
Modification of nociception and morphine tolerance by the selective opiate receptor-like orphan receptor antagonist (-)-cis-1-methyl-7-[[4-(2,6-dichlorophenyl)piperidin-1-yl]methyl]-6,7,8,9-tetrahydro-5H-benzocyclohepten-5-ol (SB-612111).
Paola Zaratin,Giuseppe Petrone,M. Sbacchi,Martine Garnier,Claudia Fossati,Paola Petrillo,Silvio Ronzoni,Giuseppe Giardina,Mark A. Scheideler +8 more
TL;DR: The data show that an ORL-1 receptor antagonist may be a useful adjunct to chronic pain therapy with opioids and can be used to treat conditions in which thermal hyperalgesia is a significant component of the pain response.
Journal ArticleDOI
In vitro and in vivo pharmacological profile of AS057278, a selective d-amino acid oxidase inhibitor with potential anti-psychotic properties.
Tiziana Adage,Anne-Cécile Trillat,Anna Quattropani,Dominique Perrin,Laurent Cavarec,Jeffrey P. Shaw,Oxana Guerassimenko,Claudio Giachetti,Beatrice Greco,Ilya Chumakov,Serge Halazy,Arthur Roach,Paola Zaratin +12 more
TL;DR: The results suggest that AS057278 has the potential to anti-psychotic action toward both cognitive and positive symptoms of schizophrenia.
Journal ArticleDOI
Setting a research agenda for progressive multiple sclerosis: the International Collaborative on Progressive MS.
Robert J. Fox,Alan J. Thompson,David Baker,Peer Baneke,Doug Brown,Paul Browne,Dhia Chandraratna,Olga Ciccarelli,Timothy Coetzee,Giancarlo Comi,Anthony Feinstein,Raj Kapoor,Karen Lee,Marco Salvetti,Kersten Sharrock,Ahmed T. Toosy,Paola Zaratin,Kim Zuidwijk +17 more
TL;DR: Tackling the impediments in developing therapies forgressive MS will require an integrated, multi-disciplinary approach to enable effective translation of research into therapies for progressive MS.